产品/疗法

CAR-T 细胞相关胆管病：首例报告的 CAR-T 细胞治疗并发症病例

Chimeric Antigen Receptor T-Cell-Associated Cholangiopathy: First Reported Case of a Complication of Chimeric Antigen Receptor T-Cell Therapy.

Brexucabtagene Autoleucel 治疗复发/难治性 B 细胞急性淋巴细胞白血病患者的临床洞见

Clinical Insights on Brexucabtagene Autoleucel for the Treatment of Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia.

伴假性进展和巨细胞病毒感染的复发性滤泡性淋巴瘤对新型抗 CD19 CAR-T 治疗的快速应答：病例报告

Rapid response in relapsed follicular lymphoma to novel anti-CD19 CAR-T therapy with pseudo-progression and cytomegalovirus infection: A case report.

CD19 CAR-T 淋巴细胞对人 B 细胞来源血液系统恶性肿瘤的免疫治疗

Immunotherapy of Hematological Malignancies of Human B-Cell Origin with CD19 CAR T Lymphocytes.

监测 CAR-T 细胞治疗疗效与应答的液体活检方法

Liquid biopsy approach to monitor the efficacy and response to CAR-T cell therapy.

在同时检测患者外周血中的 CAR-T 细胞和 B 细胞恶性肿瘤时，HDSCA-HemeCAR 工作流程可考虑用于风险监测和患者管理。

比较共刺激结构域对已获批 CD19 CAR 功能影响的复杂性

Complexities in comparing the impact of costimulatory domains on approved CD19 CAR functionality.

简讯：Brexucabtagene autoleucel（Tecartus）用于急性淋巴细胞白血病

In brief: Brexucabtagene autoleucel (Tecartus) for acute lymphoblastic leukemia.

BTK 抑制剂治疗后套细胞淋巴瘤：何时 CAR-T 并非答案？

Post-BTK inhibitor mantle cell lymphoma: When is CAR-T not the answer?

CAR-T 细胞治疗套细胞淋巴瘤

CAR T-Cell therapy for the management of mantle cell lymphoma.

CD19 CAR 抗原结合机制与亲和力调节

CD19 CAR antigen engagement mechanisms and affinity tuning.

年度重大进展：白血病

Top advances of the year: Leukemia.

CAR-T 治疗在血液系统恶性肿瘤中的历程

The journey of CAR-T therapy in hematological malignancies.

CAR-T 细胞治疗产品的免疫原性：证据、机制与减轻策略

Immunogenicity of CAR-T Cell Therapeutics: Evidence, Mechanism and Mitigation.

生产工艺对 CAR-T 细胞功能的影响

Impact of Manufacturing Procedures on CAR T Cell Functionality.

利用 CRISPR/Cas9 技术强化 CAR-T 细胞治疗应用

Strengthening the CAR-T cell therapeutic application using CRISPR/Cas9 technology.